Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Nov. 06, 2023 (GLOBE NEWSWIRE) OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and nine months ended September 30, 2023. Business highlights from the third quarter and subsequent weeks included the following: ModeX Therapeutics Inc. (ModeX) was awarded a contract from the Biomedical Advanced Research and Development Authority (BARDA) to develop novel multispecific antibodies against vi
Conference call begins at 4:30 p.m. Eastern time todayMIAMI, Aug. 03, 2023 (GLOBE NEWSWIRE) OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and six months ended June 30, 2023. Second quarter business highlights included the following: U.S. FDA approved NGENLA™ for pediatric growth hormone deficiency; OPKO earned a $90 million milestone payment from its commercial partner, Pfizer. In June 2023, the U.S. Food and Drug Administration (FDA) approved
The company is continuing its Phase 1 clinical trial evaluating the efficacy of FID-007 in treating various types of cancer. See why FLGT stock is a Hold.
Anuncian fecha de arribo de dosis de AstraZeneca paraguay.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from paraguay.com Daily Mail and Mail on Sunday newspapers.